CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on creating a new type of therapeutic molecule, RECOBIN-PROTACs, to selectively target and degrade proteins involved in acute myeloid leukemia. This approach aims to improve drug specificity and reduce side effects in cancer treatment.
Today's challenge for modern medicine is the development of tools that can selectively target cancer cells over healthy cells.
Acute myeloid leukemia (AML) is an aggressive blood cancer of the myeloid cells causing bone marrow failure.
Drug development research uses small molecules to inhibit the activity of proteins promoting cell proliferation.
The higher concentrations of drug required for efficient inhibition often lead to off-target effects.
Recent years, proteolysis targeting chimeras (PRO…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
